Proof‐of‐Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence
Alcoholism Clinical and Experimental Research2016Vol. 40(9), pp. 1935–1944
Citations Over TimeTop 10% of 2016 papers
Anke Post, Trevor Smart, Kimberley Jackson, Joanne Mann, Richard C. Mohs, Linda Rorick‐Kehn, Michael A. Statnick, Raymond F. Anton, Stephanie S. O’Malley, Conrad J. Wong
Abstract
Although not reducing the NDD, LY2940094, compared to placebo, did reduce heavy drinking days and increased abstinence days in patients with alcohol dependence.
Related Papers
- → Distinct effect of intracerebroventricular and intrathecal injections of nociceptin/orphanin FQ in the rat formalin test(1999)46 cited
- → Distinct effects of nociceptin analogs on scopolamine-induced memory impairment in mice(2008)3 cited
- → P.1.d.015 Nociceptin and [Nphe1, Arg14, Lys 15]-nociceptin-NH2, UFP-101 restored opioid antinociception in morphine tolerant mice(2006)
- → Analysis of Vasodepressor Responses to Nociceptin and Nociceptin Analogs in the Systemic Vascular Bed of the Anesthetized Rabbit In Vivo(1998)
- → Nociceptin Orphanin FQ 1-13-NH2(2007)